KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical Program.

Bruce E Sands, Marla C Dubinsky, Paulo G Kotze, Séverine Vermeire, Remo Panaccione, Millie D Long, John C Woolcott, Joseph Wu, Aoibhinn McDonnell, Martina Goetsch, Eustratios Bananis, Andres J Yarur

Inflamm Bowel Dis 31(10) 2681-2692

PMID40036804
PMCIDPMC12558578
DOI10.1093/ibd/izaf036
发表日期2025-03-04
入排依据:未发现恶性肿瘤人群证据。
已检查 3 张 PubMed Figure,均未识别为 KM 图:Graphical Abstract:AI 判定为 other;Figure 1:森林图/亚组分析图;Figure 2:森林图/亚组分析图。
摘要

摘要

BACKGROUND: Etrasimod is an oral, once daily, selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). This post hoc analysis of the ELEVATE UC clinical program describes etrasimod efficacy and safety by patients' baseline disease activity. METHODS: Predefined efficacy endpoints were assessed at week 12 in patients with moderately (modified Mayo score [MMS] 5-7) or severely (MMS 8-9) active UC using pooled data from ELEVATE UC 52 and ELEVATE UC 12. Descriptive statistics with 95% CI were calculated. RESULTS: Of 743 patients analyzed, 525 (70.7%) had moderately active and 218 (29.3%) had severely active disease at baseline. At week 12, patients treated with etrasimod showed larger mean percentage reductions (95% CI) in MMS vs placebo, regardless of baseline disease activity (-48.4% [-52.3, -44.4] vs -27.0% [-32.2, -21.7] for moderately active disease and -46.4% [-51.2, -41.5] vs -29.8% [-37.2, -22.3] for severely active disease). Similar proportions of patients with moderately or severely active disease treated with etrasimod vs placebo achieved clinical response at week 12 (61.3% vs 39.8% for moderately active disease and 64.5% vs 30.3% for severely active disease). Incidence of treatment-emergent adverse events were similar between disease activity subgroups. CONCLUSIONS: At week 12, etrasimod showed greater reductions in disease activity and higher rates of clinical response vs placebo in patients with either moderately or severely active disease at baseline. The safety profile of etrasimod was consistent with the overall trial population and was unimpacted by baseline disease activity. CLINICALTRIALS.GOV: NCT03945188; NCT03996369.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Graphical AbstractGraphical Abstract
非 KM Figure
Figure 1Figure 1. Mean percentage change (95% CI) in MMS (MMS 5–7; MMS 8–9) at week 12 and week 52 (A) and at week 12 in pooled data from both ELEVATE UC 52 AND ELEVATE UC 12 stratified by biologic/JAKi-experience subgroups according to baseline MMS (B) (FAS). Bars represent 95% CIs. Abbreviations: CI, confidence interval; FAS, full analysis set; JAKi, Janus kinase inhibitor; MMS, modified Mayo score; N , number of patients in the full analysis set at the specified time point; n , number of patients with observations at a visit; UC, ulcerative colitis.
非 KM Figure
Figure 2Figure 2. Proportion of patients achieving clinical response and each MMS category at week 12 stratified according to baseline disease activity (pooled data from ELEVATE UC 52 and ELEVATE UC 12). Lines extending from each corner are representative of each disease activity subgroup in this analysis. Patients with moderately active disease (MMS 5–7) at baseline are reflected in the lines extending from the top of the diagram with patients with severely active disease (MMS 8–9) at baseline reflected in the lines extending from the bottom of the diagram. The left and right sides represent patients treated with etrasimod and placebo, respectively. Line thickness reflects the proportions of patients who achieved clinical response (dark green line) and the proportions of patients with different levels of disease activity at week 12 (severe [red]—low [light green]; each arrow points to a decrease in disease activity). a Clinical response was defined as a ≥2-point and ≥30% decrease from baseline in MMS, and a ≥1-point decrease from baseline in RBS or RBS ≤ 1. b MMS was not available for some patients at week 12 for various reasons, including discontinuation prior to week 12. Abbreviations: MMS, modified Mayo score; RBS, rectal bleeding subscore; UC, ulcerative colitis.
非 KM Figure